The tumor-promoting flow of cells into, within and out of the tumor site: Regulation by the inflammatory axis of TNFα and Chemokines

Cancer Microenvironment

Volumn 5, Issue 2, 2012, Pages 151-164

  Ben Baruch, Adit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Angiogenesis; Chemokines; Cytokines; Inflammation; Leukocytes; Tumor necrosis factor

Indexed keywords

CHEMOKINE; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CANCER CELL; CELL COMPOSITION; CELL MIGRATION; CELL MOTILITY; CELL SUBPOPULATION; DISEASE COURSE; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INFLAMMATION; LEUKOCYTE; METASTASIS; METASTATIC SITE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; TH17 CELL; TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR PROMOTION; TUMOR SITE; TUMOR VASCULARIZATION;

EID: 84866387976     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-011-0094-3     Document Type: Review

References (175)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
2. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 140:883-899
3. Witz IP (2009) The tumor microenvironment: the making of a paradigm. Cancer Microenviron 2(Suppl 1):9-17
4. Balkwill F, Mantovani A (2010) Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 87:401-406
5. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883-899
6. Erez N, Coussens LM (2011) Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. Int J Cancer 128:2536-2544
7. Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39-51
8. De Palma M, Lewis CE (2011) Cancer: Macrophages limit chemotherapy. Nature 472:303-304
9. Bonecchi R, Locati M, Mantovani A (2011) Chemokines and cancer: a fatal attraction. Cancer Cell 19:434-435
10. Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16:133-144
11. Yadav A, Saini V, Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 411:1570-1579
12. Soria G, Ben-Baruch A (2008) The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267:271-285
13. Conti I, Rollins BJ (2004) CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 14:149-154
14. Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14:6735-6741
15. Richmond A, Yang J, Su Y (2009) The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res 22:175-186
16. Keeley EC, Mehrad B, Strieter, RM. CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res 106:91-111
17. Keeley EC, Mehrad B, Strieter RM (2008) Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 28:1928-1936
18. Fulton AM (2009) The chemokine receptors CXCR4 and CXCR3 in cancer. Curr Oncol Rep 11:125-131
19. Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9:361-371
20. Balkwill F (2006) TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 25:409-416
21. ten Hagen TL, Seynhaeve AL, Eggermont AM (2008) Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. Immunol Rev 222:299-315
22. Mocellin S, Rossi CR, Pilati P, Nitti D(2005) Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 16:35-53
23. Dinarello CA (2010)Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 29:317-329
24. Apte RN, Voronov E (2008) Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol Rev 222:222-241
25. Mantovani A, Bonecchi R, Locati M (2006) Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol 6:907-918
26. Rot A, von Andrian UH (2004) Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 22:891-928
27. Zlotnik A, Yoshie O, Nomiyama H (2006) The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 7:243
28. Laskin DL, Sunil VR, Gardner CR, Laskin JD (2011) Macrophages and tissue injury: agents of defense or destruction? Annu Rev Pharmacol Toxicol 51:267-288
29. Sedgwick JD, Riminton DS, Cyster JG, Korner H (2000) Tumor necrosis factor: a master-regulator of leukocyte movement. Immunol Today 21:110-113
30. D'Ambrosio D, Mariani M, Panina-Bordignon P, Sinigaglia F (2001) Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation. Am J Respir Crit Care Med 164:1266-1275
31. Furuichi K et al (2006) Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemiareperfusion injury. Crit Care Med 34:2447-2455
32. Shaftel SS, Carlson TJ, Olschowka JA, Kyrkanides S, Matousek SB, O'Banion MK (2007) Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophilindependent blood brain barrier permeability without overt neurodegeneration. J Neurosci 27:9301-9309
33. Kaplanski G et al (1994) Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism. Blood 84:4242-4248
34. Ben-Baruch A (ed) (2008) Expert commentary: The chemokine receptor CXCR3 and its ligands in malignancy: Do they act as double-edged swords?. Springer Publishers
35. Lapteva N, Huang XF (2010) CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther 10:725-733
36. Huang B et al (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252:86-92
37. Ali S, Lazennec G (2007) Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev 26:401-420
38. Chen JQ, Russo J (2009) ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta 1796:162-175
39. Salcedo R et al (2000) Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96:34-40
40. Lu X, Kang Y (2009) Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem 284:29087-29096
41. Karnoub AE et al (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557-563
42. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR (2003) A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 63:8360-8365
43. Ginestier C et al (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120:485-497
44. Yoo JY et al (2008) Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther 15:635-651
45. Yao C et al (2007) Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer 121:1949-1957
46. Sica A, Allavena P, Mantovani A (2008) Cancer related inflammation: the macrophage connection. Cancer Lett 267:204-215
47. Sica A et al (2008) Macrophage polarization in tumour progression. Semin Cancer Biol 18:349-355
48. Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22:231-237
49. Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29:313-326
50. Soria G, Ben-Baruch A (2009) The CCL5/CCR5 axis in cancer. Springer Publishers
51. Ben-Baruch A (2006) The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev 25:357-371
52. Ben-Baruch A (in press) The inflammatory milieu of tumors: Cytokines and chemokines that affect tumor growth and metastasismetastasis. In Ben-Baruch A (ed), Inflammatory CC chemokines in malignancy: Leukocyte migration and beyond. Bentham Science Publishers.
53. Gregory AD, Houghton AM (2011) Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 71:2411-2416
54. Wu QD, Wang JH, Condron C, Bouchier-Hayes D, Redmond HP (2001) Human neutrophils facilitate tumor cell transendothelial migration. Am J Physiol Cell Physiol 280:C814-822
55. Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL (2005) Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res 65:8896-8904
56. Fridlender ZG et al (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16:183-194
57. Vandercappellen J, Van Damme J, Struyf S (2008) The role of CXC chemokines and their receptors in cancer. Cancer Lett 267:226-244
58. Yao C, Lin Y, Ye CS, Bi J, Zhu YF, Wang SM (2007) Role of interleukin-8 in the progression of estrogen receptor-negative breast cancer. Chin Med J (Engl) 120:1766-1772
59. Salcedo R, Martins-Green M, Gertz B, Oppenheim JJ, Murphy WJ (2002) Combined administration of antibodies to human interleukin 8 and epidermal growth factor receptor results in increased antimetastatic effects on human breast carcinoma xenografts. Clin Cancer Res 8:2655-2665
60. Kim MY et al (2009) Tumor self-seeding by circulating cancer cells. Cell 139:1315-1326
61. Strell C, Lang K, Niggemann B, Zaenker KS, Entschladen F (2007) Surface molecules regulating rolling and adhesion to endothelium of neutrophil granulocytes and MDA-MB-468 breast carcinoma cells and their interaction. Cell Mol Life Sci 64:3306-3316
62. Strell C, Lang K, Niggemann B, Zaenker KS, Entschladen F (2010) Neutrophil granulocytes promote the migratory activity of MDA-MB-468 human breast carcinoma cells via ICAM-1. Exp Cell Res 316:138-148
63. Andres AC, Djonov V (2010) The mammary gland vasculature revisited. J Mammary Gland Biol Neoplasia 15:319-328
64. Patan S (2004) Vasculogenesis and angiogenesis. Cancer Treat Res 117:3-32
65. Singh S, Wu S, Varney M, Singh AP, Singh RK (2011) CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation. Microvasc Res
66. Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O (2011) Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res 71:2550-2560
67. Galvez BG et al (2005) Membrane type 1-matrix metalloproteinase is regulated by chemokines monocyte-chemoattractant protein-1/ccl2 and interleukin-8/CXCL8 in endothelial cells during angiogenesis. J Biol Chem 280:1292-1298
68. Miller LJ, Kurtzman SH, Wang Y, Anderson KH, Lindquist RR, Kreutzer DL (1998) Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res 18:77-81
69. Lin Y et al (2004) Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 109:507-515
70. Bendrik C, Dabrosin C (2009) Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol 182:371-378
71. Toulza F, Eliaou JF, Pinet V (2005) Breast tumor cell soluble factors induce monocytes to produce angiogenic but not angiostatic CXC chemokines. Int J Cancer 115:429-436
72. Stamatovic SM, Keep RF, Mostarica-Stojkovic M, Andjelkovic AV (2006) CCL2 regulates angiogenesis via activation of Ets-1 transcription factor. J Immunol 177:2651-2661
73. Weber KS, Nelson PJ, Grone HJ, Weber C (1999) Expression of CCR2 by endothelial cells: implications for MCP-1 mediated wound injury repair and In vivo inflammatory activation of endothelium. Arterioscler Thromb Vasc Biol 19:2085-2093
74. Wilson TJ, Nannuru KC, Futakuchi M, Singh RK. Cathepsin Gmediated enhanced TGF-beta signaling promotes angiogenesis via upregulation of VEGF and MCP-1. Cancer Lett 288:162-169
75. Barcelos LS, Talvani A, Teixeira AS, Cassali GD, Andrade SP, Teixeira MM (2004) Production and in vivo effects of chemokines CXCL1-3/KC and CCL2/JE in a model of inflammatory angiogenesis in mice. Inflamm Res 53:576-584
76. Ueno T et al (2000) Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6:3282-3289
77. Goede V, Brogelli L, Ziche M, Augustin HG (1999) Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 82:765-770
78. Qian BZ et al (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475:222-225
79. Valkovic T, Lucin K, Krstulja M, Dobi-Babic R, Jonjic N (1998) Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 194:335-340
80. Saji H et al (2001) Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92:1085-1091
81. Chavey C et al (2007) Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9:R15
82. Fujimoto H et al (2009) Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer 125:1276-1284
83. Soria G et al (2008) Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumorpromoting interactions. Cytokine 44:191-200
84. Neumark E, Anavi R, Witz IP, Ben-Baruch A (1999) MCP-1 expression as a potential contributor to the high malignancy phenotype of murine mammary adenocarcinoma cells. Immunol Lett 68:141-146
85. Neumark E, Cohn MA, Lukanidin E, Witz IP, Ben-Baruch A (2002) Possible co-regulation of genes associated with enhanced progression of mammary adenocarcinomas. Immunol Lett 82:111-121
86. Neumark E, Sagi-Assif O, Shalmon B, Ben-Baruch A, Witz IP (2003) Progression of mouse mammary tumors: MCP-1-TNFalpha cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. Int J Cancer 106:879-886
87. Dupre SA, Redelman D, Hunter KW Jr (2007) The mousemammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci. Int J Exp Pathol 88:351-360
88. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 184:1630-1641
89. Kurt RA, Baher A, Wisner KP, Tackitt S, Urba WJ (2001) Chemokine receptor desensitization in tumor-bearing mice. Cell Immunol 207:81-88
90. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M, Ben-Baruch A (2011) An inflammatory network in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 11:130-149
91. Luboshits G et al (1999) Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 59:4681-4687
92. Zhang Y et al (2009) Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol Rep 21:1113-1121
93. Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R (2004) Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 10:6789-6795
94. Sauer G et al (2008) Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion. Clin Cancer Res 14:3345-3353
95. Yaal-Hahoshen N et al (2006) The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 12:4474-4480
96. Luciani MG, Stoppacciaro A, Peri G, Mantovani A, Ruco LP (1998) The monocyte chemotactic protein a (MCP-1) and interleukin 8 (IL-8) in Hodgkin's disease and in solid tumours. Mol Pathol 51:273-276
97. Palkowetz KH, Royer CL, Garofalo R, Rudloff HE, Schmalstieg FC Jr, Goldman AS (1994) Production of interleukin-6 and interleukin-8 by human mammary gland epithelial cells. J Reprod Immunol 26:57-64
98. Maheshwari A, Christensen RD, Calhoun DA (2003) ELR + CXC chemokines in human milk. Cytokine 24:91-102
99. Basolo F, Conaldi PG, Fiore L, Calvo S, Toniolo A (1993) Normal breast epithelial cells produce interleukins 6 and 8 together with tumor-necrosis factor: defective IL6 expression in mammary carcinoma. Int J Cancer 55:926-930
100. Basolo F et al (1996) Expression of and response to interleukin 6 (IL6) in human mammary tumors. Cancer Res 56:3118-3122
101. Green AR, Green VL, White MC, Speirs V (1997) Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer 72:937-941
102. Speirs V, Green AR, White MC (1996) A comparative study of cytokine gene transcripts in normal and malignant breast tissue and primary cell cultures derived from the same tissue samples. Int J Cancer 66:551-556
103. Pantschenko AG et al (2003) The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol 23:269-284
104. Voss MJ, Moller MF, Powe DG, Niggemann B, Zanker KS, Entschladen F (2011) Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism. BMC Cancer 11:158
105. Chavey C et al (2008) Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-kappaB pathway in breast cancer. Mol Pharmacol 74:1359-1366
106. Freund A et al (2003) IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 22:256-265
107. Perrier S, Caldefie-Chezet F, Vasson MP (2009) IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines. FEBS Lett 583:259-265
108. Singer CF et al (2006) Interleukin-1alpha protein secretion in breast cancer is associated with poor differentiation and estrogen receptor alpha negativity. Int J Gynecol Cancer 16(Suppl 2):556-559
109. Singer CF et al (2003) Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype. Clin Cancer Res 9:4877-4883
110. Jin L et al (1997) Expression of interleukin-1beta in human breast carcinoma. Cancer 80:421-434
111. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR (1994) Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer 56:777-782
112. Pusztai L, Clover LM, Cooper K, Starkey PM, Lewis CE, McGee JO (1994) Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast. Br J Cancer 70:289-292
113. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE (1998) Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 77:2246-2251
114. Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M (2006) Role of tumor necrosis factor-alpha and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Sci 97:1044-1049
115. Berstein LM et al (2007) Signs of proinflammatory/genotoxic switch (adipogenotoxicosis) in mammary fat of breast cancer patients: role of menopausal status, estrogens and hyperglycemia. Int J Cancer 121:514-519
116. Cui LF et al (2008) Overexpression of TNF-alpha and TNFRII in invasive micropapillary carcinoma of the breast: clinicopathological correlations. Histopathology 53:381-388
117. Perrot-Applanat M et al (2011) Similar NF-kappaB gene signatures in TNF-alpha treated human endothelial cells and breast tumor biopsies. PLoS One 6:e21589
118. Shin SY, Nam JS, Lim Y, Lee YH (2010) TNFalpha-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines. J Biol Chem 285:30731-30740
119. Seeger H, Wallwiener D, Mueck AO (2008) Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis. Gynecol Endocrinol 24:576-579
120. Seeger H, Wallwiener D, Mueck AO (2006) Different effects of estradiol and various antiestrogens on TNF-alpha-induced changes of biochemical markers for growth and invasion of human breast cancer cells. Life Sci 78:1464-1468
121. Qian X, Zhang J, Liu J (2011) Tumor-secreted PGE2 inhibits CCL5 production in activated macrophages through cAMP/PKA signaling pathway. J Biol Chem 286:2111-2120
122. Ali S, Kaur J, Patel KD (2000) Intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and regulated on activation normal T cell expressed and secreted are expressed by human breast carcinoma cells and support eosinophil adhesion and activation. Am J Pathol 157:313-321
123. Azenshtein E et al (2002) The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 62:1093-1102
124. De Larco JE et al (2001) A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol 158:639-646
125. Pantschenko AG et al (2003) In vitro demonstration of breast cancer tumor cell sub-populations based on interleukin-1/tumor necrosis factor induction of interleukin-8 expression. Oncol Rep 10:1011-1017
126. Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331:1559-1564
127. Tomaskovic-Crook E, Thompson EW, Thiery JP (2009) Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 11:213
128. Zavadil J, Haley J, Kalluri R, Muthuswamy SK, Thompson E (2008) Epithelial-mesenchymal transition. Cancer Res 68:9574-9577
129. Vincent-Salomon A, Thiery JP (2003) Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 5:101-106
130. Hollier BG, Evans K, Mani SA (2009) The epithelial-tomesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 14:29-43
131. Mani SA et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715
132. Karin M, Gallagher E (2009) TNFR signaling: ubiquitin-conjugated TRAFfic signals control stop-and-go for MAPK signaling complexes. Immunol Rev 228:225-240
133. Estevam FR, Augusto SF, Rodrigues SA, Pinheiro MR, Monteiro AF (2005) Apoptosis and production of TNF-alpha by tumorassociated inflammatory cells in histological grade III breast cancer. Cancer Immunol Immunother 54:671-676
134. Gaafar A et al (2009) Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. Exp Hematol 37:838-848
135. Binder C et al (2009) Stromal endothelin B receptor-deficiency inhibits breast cancer growth and metastasis. Mol Cancer Ther 8:2452-2460
136. Jewell AN et al (2010) The endothelin axis stimulates the expression of pro-inflammatory cytokines and pro-migratory molecules in breast cancer. Cancer Invest 28:932-943
137. Das Roy L, Pathangey LB, Tinder TL, Schettini JL, Gruber HE, Mukherjee P (2009) Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Res 11:R56
138. Romieu-Mourez R et al (2010) Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming. Cancer Res 70:7742-7747
139. Zhao X, Sun X, Gao F, Luo J, Sun Z (2011) Effects of ulinastatin and docataxel on breast tumor growth and expression of IL-6, IL-8, and TNF-alpha. J Exp Clin Cancer Res 30:22
140. Warren MA, Shoemaker SF, Shealy DJ, Bshar W, Ip MM (2009) Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice. Mol Cancer Ther 8:2655-2663
141. Sangaletti S et al (2010) Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. Cancer Res 70:7764-7775
142. Hamaguchi T, Wakabayashi H, Matsumine A, Sudo A, Uchida A (2011) TNF inhibitor suppresses bone metastasis in a breast cancer cell line. Biochem Biophys Res Commun 407:525-530
143. Valdivia-Silva JE et al (2009) Effect of pro-inflammatory cytokine stimulation on human breast cancer: implications of chemokine receptor expression in cancer metastasis. Cancer Lett 283:176-185
144. Feng LY, Ou ZL, Wu FY, Shen ZZ, Shao ZM (2009) Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res 15:2962-2970
145. Vaday GG, Hershkoviz R, Rahat MA, Lahat N, Cahalon L, Lider O (2000) Fibronectin-bound TNF-alpha stimulates monocyte matrix metalloproteinase-9 expression and regulates chemotaxis. J Leukoc Biol 68:737-747
146. Robinson SC, Scott KA, Balkwill FR (2002) Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur J Immunol 32:404-412
147. Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C (2004) Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 25:1543-1549
148. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP (2009) Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 15:416-428
149. Li T et al (2011) Daintain/AIF-1 promotes breast cancer cell migration by up-regulated TNF-alpha via activate p38 MAPK signaling pathway. Breast Cancer Res Treat
150. Carpenter PM, Gatanaga T, Nguyen HP, Hiserodt JC (1997) Lymphocyte and monocyte-induced motility of MCF-7 cells by tumor necrosis factor-alpha. Int J Cancer 71:64-70
151. Mishra P, Banerjee D, Ben-Baruch A (2011) Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol 89:31-39
152. Orimo A, Weinberg RA (2006) Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 5:1597-1601
153. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392-401
154. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741-4751
155. Micalizzi DS, Farabaugh SM, Ford HL (2010) Epithelialmesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 15:117-134
156. Taylor MA, Parvani JG, Schiemann WP (2010) The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 15:169-190
157. Dong R, Wang Q, He XL, Chu YK, Lu JG, Ma QJ (2007) Role of nuclear factor kappa B and reactive oxygen species in the tumor necrosis factor-alpha-induced epithelial-mesenchymal transition of MCF-7 cells. Braz J Med Biol Res 40:1071-1078
158. Zhou C et al (2008) Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res 10: R105
159. Janji B et al (2010) The actin filament cross-linker L-plastin confers resistance to TNF-alpha in MCF-7 breast cancer cells in a phosphorylation- dependent manner. J Cell Mol Med 14:1264-1275
160. Ruike Y, Imanaka Y, Sato F, Shimizu K, Tsujimoto G (2010) Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing. BMC Genomics 11:137
161. Yin Y, Chen X, Shu Y (2009) Gene expression of the invasive phenotype of TNF-alpha-treated MCF-7 cells. Biomed Pharmacother 63:421-428
162. Cho SG et al (2009) KiSS1 suppresses TNFalpha-induced breast cancer cell invasion via an inhibition of RhoA-mediated NFkappaB activation. J Cell Biochem 107:1139-1149
163. Katoh M (2009) Integrative genomic analyses of ZEB2: Transcriptional regulation of ZEB2 based on SMADs, ETS1, HIF1alpha, POU/OCT, and NF-kappaB. Int J Oncol 34:1737-1742
164. Teng Y, Liu M, Cowell JK (2011) Functional interrelationship between the WASF3 and KISS1 metastasis-associated genes in breast cancer cells. Int J Cancer
165. Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL (2011) TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res 71:4707-4719
166. Yamauchi Y et al (2010) Tumor necrosis factor-alpha enhances both epithelial-mesenchymal transition and cell contraction induced in A549 human alveolar epithelial cells by transforming growth factor-beta1. Exp Lung Res 36:12-24
167. Camara J, Jarai G (2010) Epithelial-mesenchymal transition in primary human bronchial epithelial cells is Smad-dependent and enhanced by fibronectin and TNF-alpha. Fibrogenesis Tissue Repair 3:2
168. Kamitani S et al (2011) Simultaneous stimulation with TGF-beta1 and TNF-alpha induces epithelial mesenchymal transition in bronchial epithelial cells. Int Arch Allergy Immunol 155:119-128
169. Takahashi E et al (2010) Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelialmesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem 285:4060-4073
170. Bates RC, Mercurio AM (2003) Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 14:1790-1800
171. Borthwick LA et al (2009) Epithelial to mesenchymal transition (EMT) and airway remodelling after human lung transplantation. Thorax 64:770-777
172. Maier HJ, Schmidt-Strassburger U, Huber MA, Wiedemann EM, Beug H, Wirth T (2010) NF-kappaB promotes epithelialmesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett 295:214-228
173. Madhusudan S et al (2004) A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 10:6528-6534
174. Harrison ML et al (2007) Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 25:4542-4549
175. Brown ER et al (2008) A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol 19:1340-1346